DE29824938U1 - Pharmazeutische Zubereitung, die Clodronat als Wirkstoff und silifizierte mikrokristalline Cellulose als Exzipienten umfasst - Google Patents

Pharmazeutische Zubereitung, die Clodronat als Wirkstoff und silifizierte mikrokristalline Cellulose als Exzipienten umfasst

Info

Publication number
DE29824938U1
DE29824938U1 DE29824938U DE29824938U DE29824938U1 DE 29824938 U1 DE29824938 U1 DE 29824938U1 DE 29824938 U DE29824938 U DE 29824938U DE 29824938 U DE29824938 U DE 29824938U DE 29824938 U1 DE29824938 U1 DE 29824938U1
Authority
DE
Germany
Prior art keywords
microcrystalline cellulose
weight
preparation according
clodronate
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE29824938U
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Oy
Original Assignee
Leiras Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leiras Oy filed Critical Leiras Oy
Publication of DE29824938U1 publication Critical patent/DE29824938U1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Description

Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt

Claims (6)

1. Pharmazeutische Zubereitung, die als Wirkstoff ein pharmakologisch verträgliches Salz von Dichlormethylenbisphosphonsäure enthält, dadurch gekennzeichnet, dass es in einer oralen festen Dosierungsform ist, die silifizierte mikrokristalline Cellulose umfasst.
2. Zubereitung nach Anspruch 1, dadurch gekennzeichnet, dass es 5-25 Gew.-% silifizierte mikrokristalline Cellulose umfasst.
3. Zubereitung nach Anspruch 1, dadurch gekennzeichnet, dass es
  • a) etwa 60 bis 80 Gew.-% wasserfreies Dinatriumchlodronat;
  • b) etwa 8 bis 20 Gew.-% silifizierte mikrokristalline Cellulose; und
  • c) etwa 0,5 bis 10 Gew.-% Gleitsubstanz und/oder Abbaumittel umfasst.
4. Zubereitung nach einem der vorstehenden Ansprüche, in dem Siliciumdioxid in der silifizierten mikrokristallinen Cellulose in einer Menge von etwa 0,1 bis 20 Gew.-%, bezogen auf das Gewicht der mikrokristallinen Cellulose, vorhanden ist.
5. Zubereitung nach einem der vorstehenden Ansprüche, dadurch gekennzeichnet, dass es eine Tablette oder Kapsel ist.
6. Zubereitung nach einem der vorstehenden Ansprüche, dadurch gekennzeichnet, dass das Salz von Dichlormethylenbisphosphonsäure das Dinatriumsalz ist.
DE29824938U 1997-09-19 1998-09-18 Pharmazeutische Zubereitung, die Clodronat als Wirkstoff und silifizierte mikrokristalline Cellulose als Exzipienten umfasst Expired - Lifetime DE29824938U1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI973733A FI109088B (fi) 1997-09-19 1997-09-19 Tabletti ja menetelmä sen valmistamiseksi
EP98945336A EP1027037B1 (de) 1997-09-19 1998-09-18 Arzneimittel, das clodronat als wirkstoff und mit siliciumdioxid behandelte mikrokristalline cellulose als füllstoff enthält

Publications (1)

Publication Number Publication Date
DE29824938U1 true DE29824938U1 (de) 2003-07-31

Family

ID=8549561

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69820287T Expired - Lifetime DE69820287T2 (de) 1997-09-19 1998-09-18 Pharmazeutische Zubereitung, die Chlodronat als Wirkstoff und silicifizierte mikrokristalline Cellulose als Exipienten umfasst
DE1027037T Pending DE1027037T1 (de) 1997-09-19 1998-09-18 Arzneimittel, das clodronat als wirkstoff und mit siliciumdioxid behandelte mikrokristalline cellulose als füllsstoff enhält
DE29824938U Expired - Lifetime DE29824938U1 (de) 1997-09-19 1998-09-18 Pharmazeutische Zubereitung, die Clodronat als Wirkstoff und silifizierte mikrokristalline Cellulose als Exzipienten umfasst

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE69820287T Expired - Lifetime DE69820287T2 (de) 1997-09-19 1998-09-18 Pharmazeutische Zubereitung, die Chlodronat als Wirkstoff und silicifizierte mikrokristalline Cellulose als Exipienten umfasst
DE1027037T Pending DE1027037T1 (de) 1997-09-19 1998-09-18 Arzneimittel, das clodronat als wirkstoff und mit siliciumdioxid behandelte mikrokristalline cellulose als füllsstoff enhält

Country Status (31)

Country Link
EP (1) EP1027037B1 (de)
JP (1) JP3589977B2 (de)
KR (1) KR20010024184A (de)
CN (1) CN1124130C (de)
AT (1) ATE255410T1 (de)
AU (1) AU737738B2 (de)
BG (1) BG64886B1 (de)
BR (1) BR9812480A (de)
CA (1) CA2301185C (de)
CZ (1) CZ298675B6 (de)
DE (3) DE69820287T2 (de)
DK (1) DK1027037T3 (de)
EA (1) EA002331B1 (de)
EE (1) EE04218B1 (de)
ES (1) ES2212341T3 (de)
FI (1) FI109088B (de)
HK (1) HK1031325A1 (de)
HR (1) HRP20000142B1 (de)
HU (1) HU226118B1 (de)
ID (1) ID24423A (de)
IL (1) IL135130A (de)
IS (1) IS5404A (de)
NO (1) NO327728B1 (de)
NZ (1) NZ503766A (de)
PL (1) PL191166B1 (de)
PT (1) PT1027037E (de)
SI (1) SI1027037T1 (de)
SK (1) SK284088B6 (de)
TR (1) TR200000722T2 (de)
UA (1) UA73078C2 (de)
WO (1) WO1999015155A1 (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395303B1 (en) 1996-06-10 2002-05-28 Edward Mendell Co., Inc. Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
SE9903345D0 (sv) 1999-09-17 1999-09-17 Astra Pharma Prod Novel process
DE10006125C2 (de) * 2000-02-11 2003-08-28 Kallies Feinchemie Ag Modifizierte Mikrocellulose
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
ATE304856T1 (de) * 2000-06-20 2005-10-15 Novartis Pharma Gmbh Methode zur verabreichung von biphosphonaten
RU2288722C2 (ru) * 2000-06-20 2006-12-10 Новартис Аг Способ введения бисфосфонатов
US6753017B2 (en) 2001-11-07 2004-06-22 Jrs Pharma Lp Process for preparing dry extracts
WO2003047551A1 (en) * 2001-11-29 2003-06-12 Penwest Pharmaceutical Company Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20040109889A1 (en) 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
EP2279731B1 (de) * 2008-04-23 2012-12-12 Farmasierra Manufacturing, S.L. Ibuprofen und codein enthaltende verbesserte pharmazeutische zusammensetzung
US8603527B2 (en) * 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
SG11201404705YA (en) * 2012-02-07 2014-10-30 Biogen Idec Inc Pharmaceutical compositions containing dimethyl fumarate
US10493085B2 (en) 2012-05-14 2019-12-03 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9211257B2 (en) 2012-05-14 2015-12-15 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9999628B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10111837B2 (en) 2012-05-14 2018-10-30 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds
US8802658B2 (en) * 2012-05-14 2014-08-12 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US9700570B2 (en) 2014-05-27 2017-07-11 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9789128B2 (en) 2012-05-14 2017-10-17 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10350227B2 (en) 2012-05-14 2019-07-16 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9999629B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9669040B2 (en) 2012-05-14 2017-06-06 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10028908B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9655908B2 (en) 2012-05-14 2017-05-23 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US9782421B1 (en) 2012-05-14 2017-10-10 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US10016445B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9694023B2 (en) 2012-05-14 2017-07-04 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9616078B2 (en) 2012-05-14 2017-04-11 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US10413560B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US10463682B2 (en) 2012-05-14 2019-11-05 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
US9867839B2 (en) 2012-05-14 2018-01-16 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US9877977B2 (en) 2012-05-14 2018-01-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9770457B2 (en) 2012-05-14 2017-09-26 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesion
US20150051175A1 (en) * 2012-05-14 2015-02-19 Antecip Bioventures Ii Llc Co-Administration of Steroids and Zoledronic Acid to Prevent and Treat Pain
US9827256B2 (en) 2014-05-27 2017-11-28 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating lower back pain
US9675626B2 (en) 2012-05-14 2017-06-13 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10173986B2 (en) 2012-05-14 2019-01-08 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9717747B2 (en) 2012-05-14 2017-08-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US10028969B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9943531B2 (en) 2014-08-08 2018-04-17 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9895383B2 (en) 2012-05-14 2018-02-20 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9901589B2 (en) 2012-05-14 2018-02-27 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9956234B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US9662343B2 (en) 2012-05-14 2017-05-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9867840B2 (en) 2014-05-27 2018-01-16 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10034890B2 (en) 2012-05-14 2018-07-31 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9795622B2 (en) 2012-05-14 2017-10-24 Antecip Bioventures Ii Llc Neridronic acid for treating pain associated with a joint
US9956237B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9949993B2 (en) 2012-05-14 2018-04-24 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10039773B2 (en) 2012-05-14 2018-08-07 Antecip Bioventures Ii Llc Neridronic acid for treating arthritis
US10016446B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone
US9844559B2 (en) 2012-05-14 2017-12-19 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesions
US9707245B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10080765B2 (en) 2012-05-14 2018-09-25 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10092581B2 (en) 2014-05-15 2018-10-09 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9827192B2 (en) 2012-05-14 2017-11-28 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9861648B2 (en) 2012-05-14 2018-01-09 Antecip Boiventures Ii Llc Osteoclast inhibitors for knee conditions
US8865757B1 (en) 2014-05-28 2014-10-21 Antecip Bioventures Ii Llp Therapeutic compositions comprising imidazole and imidazolium compounds
US10004756B2 (en) 2014-05-15 2018-06-26 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9956238B2 (en) 2014-05-15 2018-05-01 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9289441B2 (en) 2014-08-08 2016-03-22 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9707247B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9820999B2 (en) 2012-05-14 2017-11-21 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9925203B2 (en) 2012-05-14 2018-03-27 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10413561B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
CN102671200B (zh) * 2012-05-29 2013-07-10 安吉东来药用辅料有限责任公司 低聚异麦芽糖片剂赋形剂、药物片剂及制备方法
CN102671203B (zh) * 2012-05-29 2013-07-10 安吉东来药用辅料有限责任公司 裙带菜多糖片剂赋形剂、药物片剂及药物片剂的制备方法
CN102698281B (zh) * 2012-05-29 2013-07-03 安吉东来药用辅料有限责任公司 海带多糖片剂赋形剂、药物片剂及药物片剂的制备方法
CN102671205B (zh) * 2012-05-29 2013-07-10 安吉东来药用辅料有限责任公司 紫菜多糖片剂赋形剂、药物片剂及药物片剂的制备方法
CN102671204B (zh) * 2012-05-29 2013-07-10 安吉东来药用辅料有限责任公司 古洛糖片剂赋形剂、药物片剂及药物片剂的制备方法
CN102698280B (zh) * 2012-05-29 2013-07-10 安吉东来药用辅料有限责任公司 塔格糖片剂赋形剂、药物片剂及药物片剂的制备方法
CN102697744B (zh) * 2012-05-29 2013-11-27 安吉东来药用辅料有限责任公司 阿洛糖片剂赋形剂、药物片剂及药物片剂的制备方法
CN102688206B (zh) * 2012-05-29 2014-08-20 石药集团中奇制药技术（石家庄）有限公司 一种匹伐他汀钙片及其制备方法
CN102671206B (zh) * 2012-05-29 2013-07-10 安吉东来药用辅料有限责任公司 低聚果糖片剂赋形剂、药物片剂及药物片剂的制备方法
US9127069B1 (en) 2014-06-11 2015-09-08 Antecip Bioventures LLC Compositions comprising rank/rankl antagonists and related compounds for treating pain
TW201629063A (zh) 2014-10-06 2016-08-16 標誌製藥公司 經取代胺基嘌呤化合物、其組合物及用其之治療方法
CN104771761A (zh) * 2015-03-19 2015-07-15 深圳国源国药有限公司 一种创新药用辅料硅化微晶纤维素及其制备方法
EA039392B1 (ru) 2016-04-01 2022-01-21 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Способ лечения рака с применением замещенного аминопуринового соединения
JP6995058B2 (ja) 2016-04-01 2022-02-21 シグナル ファーマシューティカルズ，エルエルシー （１ｓ，４ｓ）－４－（２－（（（３ｓ，４ｒ）－３－フルオロテトラヒドロ－２ｈ－ピラン－４－イル）アミノ）－８－（（２，４，６－トリクロロフェニル）アミノ）－９ｈ－プリン－９－イル）－１－メチルクロロヘキサン－１－カルボキサミドの固体形態及びその使用方法
JP2020536100A (ja) 2017-10-04 2020-12-10 セルジーン コーポレイション シス−４−［２−｛［（３ｓ，４ｒ）−３−フルオロキサン−４−イル］アミノ｝−８−（２，４，６−トリクロロアニリノ）−９ｈ−プリン−９−イル］−１−メチルシクロヘキサン−１−カルボキサミドの製造プロセス
KR20200062270A (ko) 2017-10-04 2020-06-03 셀진 코포레이션 시스-4-[2-｛[(3s,4r)-3-플루오로옥산-4-일]아미노｝-8-(2,4,6-트리클로로아닐리노)-9h-퓨린-9-일]-1-메틸시클로헥산-1-카르복스아미드의 조성물 및 이용 방법
CN110787140A (zh) * 2018-08-01 2020-02-14 北京万全德众医药生物技术有限公司 比拉斯汀片剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE60711T1 (de) * 1986-12-20 1991-02-15 Boehringer Mannheim Gmbh Clodronat-haltige arzneimittel und verfahren zur herstellung derselben.
DE59300688D1 (de) * 1993-05-15 1995-11-02 Boehringer Mannheim Gmbh Tablette mit verbesserter Bioverfügbarkeit enthaltend Dichlormethylendiphosphonsäure als Wirkstoff.
FI94926C (fi) * 1993-11-12 1995-11-27 Leiras Oy Menetelmä klodronaattivalmisteen valmistamiseksi
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability

Also Published As

Publication number Publication date
KR20010024184A (ko) 2001-03-26
JP2001517616A (ja) 2001-10-09
DE1027037T1 (de) 2002-11-28
CN1270516A (zh) 2000-10-18
BR9812480A (pt) 2000-09-26
EP1027037A1 (de) 2000-08-16
JP3589977B2 (ja) 2004-11-17
FI109088B (fi) 2002-05-31
WO1999015155A1 (en) 1999-04-01
HK1031325A1 (en) 2001-06-15
SK3932000A3 (en) 2000-11-07
EE200000096A (et) 2000-12-15
CZ298675B6 (cs) 2007-12-19
CZ2000787A3 (cs) 2000-08-16
EE04218B1 (et) 2004-02-16
EP1027037B1 (de) 2003-12-03
UA73078C2 (uk) 2005-06-15
DE69820287T2 (de) 2004-10-14
HUP0004383A3 (en) 2006-06-28
FI973733A (fi) 1999-03-20
EA002331B1 (ru) 2002-04-25
CN1124130C (zh) 2003-10-15
HUP0004383A2 (hu) 2001-08-28
CA2301185A1 (en) 1999-04-01
HRP20000142A2 (en) 2000-06-30
HRP20000142B1 (en) 2004-06-30
IS5404A (is) 2000-03-14
ES2212341T3 (es) 2004-07-16
BG64886B1 (bg) 2006-08-31
SK284088B6 (sk) 2004-09-08
BG104265A (en) 2000-11-30
CA2301185C (en) 2006-11-28
NO20001417D0 (no) 2000-03-17
ATE255410T1 (de) 2003-12-15
SI1027037T1 (en) 2004-04-30
NO20001417L (no) 2000-05-19
ID24423A (id) 2000-07-20
PT1027037E (pt) 2004-04-30
IL135130A (en) 2004-09-27
HU226118B1 (en) 2008-04-28
AU737738B2 (en) 2001-08-30
DK1027037T3 (da) 2004-03-15
EA200000317A1 (ru) 2000-10-30
IL135130A0 (en) 2001-05-20
PL191166B1 (pl) 2006-03-31
TR200000722T2 (tr) 2000-11-21
AU9268598A (en) 1999-04-12
FI973733A0 (fi) 1997-09-19
NZ503766A (en) 2002-02-01
NO327728B1 (no) 2009-09-14
DE69820287D1 (de) 2004-01-15
PL339290A1 (en) 2000-12-04

Similar Documents

Publication Publication Date Title
DE29824938U1 (de) Pharmazeutische Zubereitung, die Clodronat als Wirkstoff und silifizierte mikrokristalline Cellulose als Exzipienten umfasst
ATE128028T1 (de) Pharmazeutische zubereitung in form einer brause- und/oder zerfallstablette oder eines instantgranulats, sowie verfahren zu ihrer herstellung.
HUT50631A (en) Process for producing long-acting pharmaceutical compositions comprising etodolac active ingredient
UA26455C2 (uk) Лікарський препарат у формі таблеток із сповільhеhим вивільhеhhям активhого іhгредієhта
ATE69378T1 (de) Pharmazeutische zusammensetzungen.
MY126625A (en) Compositions containing diphosphonic acids
CA2232310A1 (en) Stable compositions containing n-propargyl-1-aminoindan
CA2029599A1 (en) Medicaments containing as active substance sulphur-containing carboxylic acids and their use in combating retroviruses
ES2071621T3 (es) Enantiomero dextrogiro del alfa-(tetrahidro-4,5,6,7-tieno-(3,2-c)-piridil-5)(cloro-2-fenil) acetato de metilo, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen.
UA27749C2 (uk) Заміщені циклопропіламіно-1,3,5-триазини, їх оптичні ізомери, рацемічні суміші чи їх солі приєднання нетоксичних фармацевтично прийнятних кислот, що мають фармакологічну активність, спосіб їх одержання (варіанти) та фармацевтична композиція на їх основі
CA2009593A1 (en) Medicament containing dihydrolipoic acid as active substance
HUT53071A (en) Process for producing aryl compounds with antinflammatory activity and pharmaceutical compositions comprising such active ingredient
AU616134B2 (en) 2-alkyl-3-benzoylbenzofurans and pharmaceutical compositions containing them
DE3136031C2 (de)
SI9620036B (sl) Derivat aminotetralina za terapijo kardiovaskularnih bolezni
EP0285871A3 (en) Sustained release granulate without binding agent
DE20115218U1 (de) Amid-Derivat von Amlodipin
EP0132880B1 (de) Pharmazeutische Zusammenstellungen, die Epinine oder ein pharmazeutisches annehmbares Salz enthalten
DE2724608C2 (de) 1-(4-Isopropylthiophenyl)-2-n-octylaminopropanol enthaltende pharmazeutische Zubereitung
KR920703067A (ko) 말초 신경질환 및 뇌질환 치료용 L-α-글리세로포르포릴-D-미오-이노시톨
DE3231088A1 (de) (-)-cis-2.8-dimethyl-2.3.4.4a.5.9b-hexahydro-1h-pyrido-(4.3-b)indol, seine herstellung und pharmazeutische mittel, insbesondere antiarrythmika
EP0461218B1 (de) Zubereitung eines salzes von oxypurinol in oraler form zur behandlung von hyperuricämie
DE2532180C2 (de) Verwendung von Etozolin bei der Bekämpfung der Hypertonie
IE35492B1 (en) 2-benzylphenols their preparation and compositions containing them
Prystowsky et al. Evidence supporting a direct cholinergic effect on ventricular muscle refractory period in man

Legal Events

Date Code Title Description
R207 Utility model specification

Effective date: 20030904

R081 Change of applicant/patentee

Owner name: SCHERING OY, FI

Free format text: FORMER OWNER: LEIRAS OY, TURKU, FI

Effective date: 20030716

R150 Utility model maintained after payment of first maintenance fee after three years

Effective date: 20031022

R151 Utility model maintained after payment of second maintenance fee after six years

Effective date: 20040628

R158 Lapse of ip right after 8 years

Effective date: 20070403